CAS: 106133-20-4; (R)-5-(2-((2-(2-Ethoxyphenoxy)Ethyl)Amino)Propyl)-2-Methoxybenzenesulfonamide

该化合物是一种选择性的甲型-甲型肾上腺激素对抗物,主要用于治疗良性先质增生(BPH),以缓解尿症症状;通过放松前列腺和膀胱颈的光滑肌肉,方便尿道;Tamsulsin的化学配方为C20H28N2O5S,并具有有助于其药理活动的磺酰胺组;Tamsulosin的特点是口服生物利用率高,半衰期相对较长,允许每日服一次药.通常以胶囊的形式施用.该物质具有有利的副作用,与非选择性的甲型阻塞剂相比,其心血管影响较低.但是,它仍然可能造成副作用,如眩晕,头痛和异常的乳液化.Tamsulosin被归类为处方药,应在医疗监督下使用,特别是在有心部低能或采取其他抗药的病人中.

结构式图片

上下游产品

2-(2-ethoxyphenoxy)acetaldehyde (S)-5-(2-hydroxypropyl)-2-methoxybenzenesulfonamide (R)-5-(2-azidopropyl)-2-methoxybenzenesulfonamide (S)-1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl acetatetamsulosin hydr°Chloride (R)-tamsar°Cin (-)-camphor-10-sulfonate tamsulosin hydr°Chloride (R)-tamsulosin(+)-tartrate salt

合成工艺路线路线简述

  • 合成目标产物 Tamsulosin 主要起始原料 2-(2-Ethoxyphenoxy)Ethyl Methanesulfonate And R-(-)-5-(2-Amino-Propyl)-2-Methoxy-Benzenesulfonamide
  • (文献来源)合成步骤主要原料 2-(2-Ethoxyphenoxy)Ethyl Methanesulfonate 和 R-(-)-5-(2-Amino-Propyl)-2-Methoxy-Benzenesulfonamide
5-((R)-2-((2-(2-Ethoxy)Phenoxyethyl)((R)-1-Phenylethyl)Amino)Propyl)-2-Methoxybenzenesulfonamide置于甲醇,Palladium 10% On Activated Carbon,甲酸铵体系中,用76.5%的收率获得坦索洛新
参考文献:一种盐酸坦索罗辛的制备方法
标题:一种盐酸坦索罗辛的制备方法
摘要:本发明属于化学合成技术领域,涉及一种盐酸坦索罗辛的合成方法.该合成方法将如式(II)所示的苯磺酰胺先与式(III)所示的溴醚反应得到如式(iv)所示的缩合物中间体,中间体式(iv)在甲酸铵及催化剂的存在下,转移氢化反应后,得到如式(v)所示的r‑坦索罗辛游离碱,该r‑坦索罗辛游离碱在有机溶剂中与盐酸进行成盐反应,得到如式(i)所示的盐酸坦索罗辛.其特征在于,其中式(II)与式(III)反应是在含有水的溶剂中进行的.通过本发明的合成路线,得到的盐酸坦索罗辛的反应过程中不存在两分子的溴化物与胺反应生成二取代副产物,获得的盐酸坦索罗辛具有产品纯度好,质量稳定,收率高,本发明的反应条件温和,合成方便.

专利信息


专利号:US-9353057-B2
优先权日:2003-12-30
标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA
权利人:XENOPORT INC
摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

专利号:US-8193384-B2
优先权日:2005-07-29
标 题 :Polymer-bound phosphitylating reagents for the synthesis of organophosphorus compounds
发明人:PARANG KEYKAVOUS; AHAMDIBENI YOUSEF
权利人:PARANG KEYKAVOUS; AHAMDIBENI YOUSEF; RHODE ISLAND EDUCATION
摘要:The synthesis and biochemical utility of modified oligonucleotides containing diphosphodiester internucleotide linkages. The synthesis of these compounds was carried out using diphosphitylating reagents. Oligonucleotides containing diphosphate diester bridges wherein said oligonucleotides are synthesized via a solid-phase synthesis strategy to form modified oligonucleotides. Diphosphitylating, triphosphitylating, tetraphosphitylating, β-triphosphitylating, bifunctional diphosphitylating, bifunctional triphosphitylating, and bifunctional tetraphosphitylating reagents wherein, the phosphorus atoms are linked together through oxygen, sulfur, amino, or methylene groups and/or are substituted with chlorine, diisopropylamine and cyanoethoxy groups.

专利号:US-2012177593-A1
优先权日:2009-07-20
标 题 :Synthesis of dendrimer conjugates
发明人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

专利号:WO-2012101648-A1
优先权日:2011-01-24
标题:Novel process for the synthesis of enantiomerically pure 2-methoxy-5-[(2r)-2-(4-alkylpiperazin-l-yl)propyl]-benzenesulfonamide
发明人:HAVALDAR FREDDY H; DABHOLKAR BHUSHAN VASANT; MULE GANESH BABAN
权利人:HAVALDAR FREDDY H
摘要:Where R is C1-C3 alkyl, alkenyl A novel process for synthesis of compound of Formula 1 comprising steroselective catalytic reduction of compound of Formula IV under hydrogen gas pressure to obtain an intermediate compound of Formula II, which on coupling in presence of coupling agent and base in presence of organic solvent to obtain compound of Formula X, Formula X on reacting with deprotecting agent in presence of organic solvent results in formation of compound of Formula XI, condensation of Formula XI with alkyl halide results in formation of compound of Formula I.

专利号:US-7619116-B2
优先权日:2003-12-17
标 题:Intermediates for the synthesis of (R)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation
发明人:DAMBRIN VALERY; LENOIR JEAN-YVES; SCHNEIDER JEAN-MARIE; GUILLAMOT GERARD; FOLLET MICHEL; BECKER ABRAM
权利人:PRODUCTS CHIMIQUES AUXILIAIRES
摘要:A subject matter of the present invention is novel intermediates for the synthesis of (R)-tamsulosin and of its pharmaceutically acceptable salts, and also the associated preparation process.

专利号:US-7538246-B2
优先权日:2003-12-29
标 题:Synthesis of optically pure(r)-5-(2-amynopropyl)-2-methoxybenzenesulphonamide
发明人:MOHAR BARBARA
权利人:LEK PHARMACEUTICALS
摘要:The present invention relates to a new process for the preparation of optically pure(R)-5-(2-aminopropyl)-2-methoxybenzenesulphonamide, which is an intermediate in the synthesis of tamsulosin.
杭州鼎燕化工有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.dingyanchem.com
企业联系电话:18267553885👤
📞杭州鼎燕化工有限公司 ⚠️参考联系方式
联系人:林女士
电话:18267553885
手机:18267553885
传真:0571-87156470
邮箱:sales@dingyanchem.com
通信地址: 杭州市江干区下沙19号大街571号下沙电子商务园4A601-602室
邮编: 310018
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:杭州市江干区下沙19号大街571号下沙电子商务园4A601-602室
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
常州瑞明药业股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.ruimingpharm.com
企业联系电话:0519-86920910;18261172629;18118380910👤
📞常州瑞明药业股份有限公司 ⚠️参考联系方式
联系人:夏文华
电话:0519-86920910;18261172629;18118380910
手机:18261172629;18118380910
传真:0519-86920912
邮箱:swm@ruimingpharm.com
通信地址: 江苏省常州市龙江北路1558号
邮编: 213127
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:江苏省常州市龙江北路1558号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Morones J, Pérez M, Muñoz M, Sánchez E, Ávila M, Topete J, Ventura J, Martínez S. Evaluation of the Effect of an α-Adrenergic Blocker, a PPAR-γ Receptor Agonist, and a Glycemic Regulator on Chronic Kidney Disease in Diabetic Rats. Int J Mol Sci. 2024 Oct 23;25(21):11372. doi: 10.3390/ijms252111372.
2: Domínguez-Millán R, Pisciotti TL, Cuesta PF, Becerril MAB. Fowler syndrome post liposculpture and augmentation mammoplasty: Case report and literature review. JPRAS Open. 2024 Sep 26;42:292-295. doi: 10.1016/j.jpra.2024.09.013.
3: Bumbuluț B, Stănilă DM. Floppy iris. How is floppy iris syndrome managed? What do urologists and ophthalmologists say? Rom J Ophthalmol. 2024 Jul- Sep;68(3):301-305. doi: 10.22336/rjo.2024.54.

合成参考文献


参考文献:10.1111/j.1365-2125.2010.03870.x
摘要:Korstanje C, Krauwinkel W, van Doesum‐Wolters FLC. Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity Brit J Clinical Pharma. 2011 Jul 11;72(2):218–25. doi: 10.1111/j.1365-2125.2010.03870.x.
参考文献:10.1001/archinternmed.2011.297
摘要:Veysman BD. Good research leads to better care. Arch Intern Med. 2011 Jul 11;171(13):1216; author rely 1216–7. doi: 10.1001/archinternmed.2011.297.
参考文献:10.4111/kju.2011.52.6.406
摘要:Jang DG, Yoo C, Oh CY, Kim SJ, Kim SI, Kim CI, Kim HS, Park JY, Seong do H, Song YS, Yang WJ, Cho IR, Cho SY, Cheon SH, Im H, Cho JS. Current status of transurethral prostatectomy: a korean multicenter study. Korean J Urol. 2011 Jun;52(6):406–9.
参考文献:10.1007/s12350-011-9426-4
摘要:Haleem K, Malm B. Ischemic electrocardiogram during pharmacologic stress with regadenoson. J Nucl Cardiol. 2011 Oct;18(5):978–80. doi: 10.1007/s12350-011-9426-4.
参考文献:10.2147/cia.s13803
摘要:Yoshida M, Kudoh J, Homma Y, Kawabe K. Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clin Interv Aging. 2011;6():161–72.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知